Real-World Study Shows INVOKANA ® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Invokana | Pharmaceuticals | Study